372 chapter 6 Observation after (c)TT for malignancy 1st year €1,949 [29, 176, 467, 476] ±25% 0.07 [29, 176, 495, 564] 0.03-0.12 2nd-15th year €753 [29, 176, 467, 476] ±25% 0.04 [29, 176, 495, 564] 0.02-0.07 16th year onwards €0 [467] ±25% 0.02 Expert opinion 0.00-0.05 Transient complication due to (c)TT €1,106 [29, 158, 176, 178, 476, 495, 496, 563] ±25% 0.06 [29, 176, 495] 0.02-0.11 Permanent complication due to (c)TT 1st year €3,462 [29, 158, 176, 178, 495, 496, 558, 562, 563] ±25% 0.35 [29, 176, 495] 0.26–0.45 2nd year onwards €722 [29, 158, 176, 495, 562, 563] ±25% 0.35 [29, 176, 495] 0.26–0.45 Recurrence after (c)TT €1,452 [29, 176] ±25% 0.40 [29, 176] 0.31–0.50 Death €0 Convention 0 Convention Fixed Other health-care related costs, yearly costs Other health care consumptiond €2,511 EfFECTS Travel expenses for thyroid-related health caree €12-€105 EfFECTS ±25% Travel expenses for other health care consumptiond € 99 EfFECTS Informal cared € 604 EfFECTS Productivity losses, yearly Productivity losses due to HT HT for benign nodule €3,065 EfFECTS € 620 (SD) HT for malignant nodule €3,925 EfFECTS € 1,238 (SD) Productivity losses due to (c)TT €4,686 [565-568], EfFECTS € 1,028 (SD) Productivity losses due to RAI €1,188 [568-572], expert opinion € 292 (SD) Yearly productivity losses for recurrent/ progressive malignant disease €2,493 [565-567, 569, 573-575] ±25% Yearly other paid productivity lossesd € 2,267 EfFECTS Yearly unpaid productivity lossesd € 1,153 EfFECTS a: Ranges are for triangular parameter distributions (with mode equal to the base-case value). b: Subtracted from age and sex dependent utilities [474]. c: Active surveillance was defined as a yearly visit to the endocrinologist and an ultrasound of the neck every 12-24 months. d: Linear regression analysis was performed using the first-year trial data to establish estimates for this variable, including sex, age, and estimated QALYs as predictors. Reported values in this table are parameter means; more detailed regression analysis data, including uncertainty, are provided in Supplementary data, Table 1. e: Costs are dependent on the model health state, see Supplementary data, Table 2. HT, hemithyroidectomy. (c)TT, (completing) total thyroidectomy. EfFECTS, observed data from the first year of the EfFECTS trial were included as a source. RAI, radioiodine ablative therapy. SD, standard deviation.
RkJQdWJsaXNoZXIy MTk4NDMw